We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Dermatology

Journal Scan / Research · October 19, 2020

Secukinumab and Expression of ACE2 in Affected Skin of Patients With Psoriasis

Journal of Allergy and Clinical Immunology

 

Additional Info

Journal of Allergy and Clinical Immunology
Secukinumab Lowers Expression of ACE2 in Affected Skin of Patients With Psoriasis
J. Allergy Clin. Immunol 2020 Sep 28;[EPub Ahead of Print], JG Krueger, DF Murrell, S Garcet, K Navrazhina, PC Lee, E Muscianisi, A Blauvelt

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading